News
Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...
The FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with ...
Researchers at Mayo Clinic are investigating why multiple myeloma is the most common cancer in the Black community.
The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...
Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...
"Back in the 1990s, multiple myeloma was a dreaded disease and patients had dismal outcomes," Vishwanath Sathyanarayanan, MD, DM, of Apollo Cancer Centers in Bangalore, India, said in an interview.
The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...
For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: C=Hypercalcemia R=Renal insufficiency A=Anemia B ...
Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment efficiency in the IRAKLIA study.
The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.
Signs and Symptoms That Occur With Multiple Myeloma As cancerous plasma cells multiply within the bone marrow, they reveal their presence in a number of ways. The main three tend to be: Bone Pain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results